KRAS and colorectal carcinoma: On the other hand, although the absolute role of each KRAS mutation allele is in question with regard to CRC response to cetuximab [7], the activation status of the RAS signaling pathway downstream of EGFR could still play a role in clinical response to anti-EGFR therapies [21].